Literature DB >> 30166087

Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?

Bridget F Collins1, Robyn L McClelland2, Lawrence A Ho1, Carmen R Mikacenic1, Jennifer Hayes1, Carolyn Spada1, Ganesh Raghu3.   

Abstract

BACKGROUND: Idiopathic Pulmonary Fibrosis (IPF) and Sarcoidosis are distinct clinical entities. Fibrotic disease in pulmonary sarcoidosis is typically upper lobe predominant. In IPF fibrosis is basilar and peripheral predominant [usual interstitial pneumonia (UIP) pattern]. Sarcoidosis and UIP have rarely been observed in the same patient. We sought to characterize patients manifesting both sarcoidosis and IPF and compare clinical features and survival to that of patients with "Lone-IPF" (IPF only) and pulmonary sarcoidosis with fibrosis in a non-UIP pattern.
METHODS: Patients were identified from a clinical database and data abstracted from medical records (1995-2016): 1) 25 patients with combined sarcoidosis and IPF (CSIPF) defined by clinical and histological features of sarcoidosis and HRCT features of possible or definite UIP or UIP by histopathology; 2) Randomly selected control patients during the same period: 28 Lone-IPF, 25 stage III/IV pulmonary sarcoidosis.
RESULTS: The gender and race of patients with CSIPF and Lone-IPF patients were similar (68% male and 84% Caucasian), as were survival outcomes. Mean time from IPF diagnosis to death: 3.2 years CSIPF, 3.6 years Lone-IPF (log rank p value 0.49). Among patients with pulmonary sarcoidosis, mean time from diagnosis to death: 21.4 years.
CONCLUSIONS: Clinical characteristics/behavior of patients with CSIPF was similar to Lone-IPF patients. It is possible that patients with sarcoidosis coincidentally developed IPF and/or have occult genetic predisposition factors to manifest both diseases at different time points. Further study is needed.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Interstitial lung disease; Sarcoidosis; Usual interstitial pneumonia

Mesh:

Year:  2018        PMID: 30166087     DOI: 10.1016/j.rmed.2018.08.008

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

Review 1.  Contemporary optimized practice in the management of pulmonary sarcoidosis.

Authors:  Shambhu Aryal; Steven D Nathan
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

2.  Honeycomb lung-like structures resulting from clustering of traction bronchiectasis distally in sarcoidosis.

Authors:  Michiru Sawahata; Noriharu Shijubo; Takeshi Johkoh; Koichi Hagiwara; Satoshi Konno; Tetsuo Yamaguchi
Journal:  Respirol Case Rep       Date:  2020-03-08

Review 3.  Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series.

Authors:  Laura Bergantini; Gabriele Nardelli; Miriana d'Alessandro; Giusy Montuori; Caterina Piccioli; Elisabetta Rosi; Sara Gangi; Dalila Cavallaro; Paolo Cameli; Elena Bargagli
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

4.  The UIP/IPF fibroblastic focus is a collagen biosynthesis factory embedded in a distinct extracellular matrix.

Authors:  Jeremy A Herrera; Lewis Dingle; M Angeles Montero; Rajamiyer V Venkateswaran; John F Blaikley; Craig Lawless; Martin A Schwartz
Journal:  JCI Insight       Date:  2022-08-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.